Publicaciones

  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007

Tau mRNA 3'UTR-to-CDS ratio is increased in Alzheimer disease.
García-Escudero V, Gargini R, Martín-Maestro P, García E, García-Escudero R, Avila J.
Neurosci Lett. 2017 Aug 10;655:101-108. doi: 10.1016/j.neulet.2017.07.007. Epub 2017 Jul 8.
PMID: 28689927

A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers.
Pisignano G, Napoli S, Magistri M, Mapelli SN, Pastori C, Di Marco S, Civenni G, Albino D, Enriquez C, Allegrini S, Mitra A, D'Ambrosio G, Mello-Grand M, Chiorino G, Garcia-Escudero R, Varani G, Carbone GM, Catapano CV.
Nat Commun. 2017 May 30;8:15622. doi: 10.1038/ncomms15622.
PMID: 28555645

Inefficient differentiation response to cell cycle stress leads to genomic instability and malignant progression of squamous carcinoma cells.
Alonso-Lecue P, de Pedro I, Coulon V, Molinuevo R, Lorz C, Segrelles C, Ceballos L, López-Aventín D, García-Valtuille A, Bernal JM, Mazorra F, Pujol RM, Paramio J, Ramón Sanz J, Freije A, Toll A, Gandarillas A.
Cell Death Dis. 2017 Jun 29;8(6):e2901. doi: 10.1038/cddis.2017.259.
PMID: 28661481

IKKβ-Mediated Resistance to Skin Cancer Development Is Ink4a/Arf-Dependent.
Page A, Bravo A, Suarez-Cabrera C, Alameda JP, Casanova ML, Lorz C, Segrelles C, Segovia JC, Paramio JM, Navarro M, Ramirez A.
Mol Cancer Res. 2017 Jun 5. doi: 10.1158/1541-7786.MCR-17-0157.
PMID: 28584022
 
Epigenetic mutations and cancer therapy Effectiven(EZH2).
Segovia C, Paramio JM, Martínez-Fernández M.
Translational Cancer Research 2017; 6, Supplement 3 (May 2017): S629-S634
 
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.
Puente J, Laínez N, Dueñas M, Méndez-Vidal MJ, Esteban E, Castellano D, Martinez-Fernández M, Basterretxea L, Juan-Fita MJ, Antón L, León L, Lambea J, Pérez-Valderrama B, Vázquez S, Suarez C, Del Muro XG, Gallardo E, Maroto JP, Samaniego ML, Suárez-Paniagua B, Sanz J, Paramio JM; SOGUG (Spanish Oncology Genitourinary Group).
Oncotarget. 2017 May 2;8(18):30410-30421. doi: 10.18632/oncotarget.16494.
 
Clusterization in head and neck squamous carcinomas based on lncRNA expression: molecular and clinical correlates
de Lena PG, Paz-Gallardo A, Paramio JM and García-Escudero R
Clinical Epigenetics 2017 9:36 DOI: 10.1186/s13148-017-0334-6
 
UroMark—a urinary biomarker assay for the detection of bladder cancer
Feber A, Dhami P, Dong L, de Winter P, Tan WS, Martínez-Fernández M, Paul DS, Hynes-Allen A, Rezaee S, Gurung P, Rodney S, Mehmood A, Villacampa F, de la Rosa F, Jameson C, Cheng KK, Zeegers MP, Bryan RT, James ND, Paramio JM, Freeman A, Beck S, Kelly JD.
Clinical Epigenetics 2017 9:8   DOI: 10.1186/s13148-016-0303-5
 
A transposon-based analysis reveals RASA1 is involved in triple negative breast cancer
Suárez-Cabrera C, Quintana RM, Bravo A, Casanova ML, Page A, Alameda JP, Paramio JM, Maroto AM, Salamanca J, Dupuy AJ, Ramírez A, Navarro M.

Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.
Segovia C, Martínez-Fernández M, Dueñas M, Rubio C, López-Calderón FF, Costa C, Saiz-Ladera C, Fernández-Grajera M, Duarte J, García Muñoz H, de la Rosa F, Villacampa F, Castellano D, Paramio JM.
Oncotarget. 2017 Jan 2. doi: 10.18632/oncotarget.14453. [Epub ahead of print]
PMID: 28060766